How Janssen R&D Accelerates Monoclonal Cell Line Development Using Cyto-Mine®
Summary
Explore how Janssen R&D’s Cell Line Development team used Sphere Fluidics’ Cyto-Mine® platform to streamline their monoclonal antibody production process. This high-throughput microfluidic technology enabled rapid single-cell encapsulation, analysis, sorting, imaging, and dispensing—integrated into a single-use cartridge system. The approach significantly reduced timelines and resources while maintaining productivity and monoclonality standards.
Research highlights
- Paper Title: Rapid Generation of High-Producing Clonal Cell Lines
- Authors: Thomas Kelly, Angela M. Tuckowski, Kevin D. Smith
- Published: 2018
- Key Benefits:
- FRET-based productivity screening
- Single-use cartridges reduce contamination risk
- Shortens cell line development timeline by 4–6 weeks
Key findings
In this study, Janssen R&D integrated Cyto-Mine® technology to reduce the need for multiple devices in the cell-line development process. By encapsulating, sorting, and imaging cells within one microfluidic instrument, they achieved efficient high-yield clonal cell lines faster and with less resource expenditure.
Why Cyto-Mine®?
Learn how Cyto-Mine® supports leading-edge research in antibody discovery, enabling scientists to isolate the best candidates with precision and efficiency. Visit our Cyto-Mine® product page to explore the technology that is empowering today’s breakthroughs in biotherapeutics.
The Next Generation: Cyto-Mine® Chroma
Automate. Accelerate. Analyze millions of cells in a single day.
Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.
